*American Association for the Study of Liver Diseases

Investigators also found that opiate agonist therapy could have a positive effect in limiting reinfection rates after patients achieve SVR.

For patients with chronic liver disease, opioid prescriptions are common, and high-risk prescriptions are associated with hepatic decompensation, especially ascites.

ALD-related hospitalizations grew from 2008 to 2014, especially among women, Asians, Hispanics, and people 50 to 69 years of age.

No studies to-date have looked at the combined risk of mortality for patients with thrombocytopenia and severe hepatic steatosis.

The leading etiologies for chronic-liver-disease-related-deaths over the last decade can be explained by NAFLD and alcoholic liver disease.

A new study confirms that HCV-RNA can be found in the nasal and rectal fluids of patients with high viral loads of HCV, raising the possibility of HCV transmission via these fluids.

A low dose of TDF may help to preserve renal function and maintain viral suppression in patients with chronic hepatitis B virus infection, even those with advanced liver disease.

After the therapy was approved by the FDA in May, investigators are anticipating its first real-world data will paint a clearer picture of its potential.

Cirrhotic patients with variceal bleeding were found to have greater morbidity in association with obesity.

How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.

HRS-1 is a rare, acute complication of liver cirrhosis characterized by life-threatening and rapid progression that can end in renal failure. Terlipressin, a vasopressin analogue, could become the first therapy approved for the treatment of HRS-1 in the US.

Norah Terrault, MPH, MD, explains how the use of cannabis can affect a patient's status on the liver transplant list.

Norah Terrault, MPH, MD, discusses gaps in treatment in people who are infected with hepatitis C virus and what steps clinicians should take when treating these patients.

The new approach could shave off time and costs from the current standard regimen.

At 12 weeks post treatment per protocol analysis with 8 weeks of glecaprevir/pibrentasvir treatment, patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response.

Norah Terrault, MPH, MD, addresses the many unanswered questions and data surrounding cannabis use in liver disease.

Investigators praised the excellent effectiveness of both therapies, but advised care regarding the increased odds of adverse events requiring hospitalizations.

Clostridium difficile infection leads to higher rates of overall mortality among patients with cirrhosis compared to those who do not have the condition.

The use of mood-altering medications does not increase odds for hepatic encephalopathy or hepatic encephalopathy-related hospital admissions after TIPS placement, according to the results of a new study.

People who inject drugs who are infected with hepatitis C virus can achieve sustained viral response at the completion of treatment, despite imperfect adherence.

Research on nonalcoholic fatty liver disease in persons infected with HIV revealed a prevalence of the condition of about 40%.

Although acute kidney injury is common in patients with cirrhosis, those who are admitted to the hospital are at increased risk, especially if they are of older age, Child-Pugh Class C, or have ascites or sepsis.

Data from a phase 2, double-blind, placebo-controlled study, showed a higher dose of simvastatin was associated with greater liver and muscle toxicity compared with a lower dose for patients with decompensated cirrhosis.

Treatment was also successful in patients with prior noncompletion or poor adherence to direct-acting antiviral therapy.

Obese patients who underwent weight-loss surgery prior to receiving a liver transplant had a significantly lower risk of metabolic complications post-transplant than those who followed medical weight loss prior to transplant.

The first results of a study on the use of monthly RNAi with ARO-HBV in patients with chronic hepatitis B virus infections indicate that the treatment effectively reduced all measurable viral products, including HBsAg.

The biology of thrombopoietin metabolism in advanced liver disease may be influenced by platelet count and degree of liver failure.

In the effort to help the growing number of people with liver disease new medications are constantly being developed. This is true for a wide range of conditions including cirrhosis and fibrosis.

A considerable amount of research has been done looking at how liver disease can progress in patients, but a recent study looked at possible regression in conditions like cirrhosis and fibrosis.

In the past, patients deemed obese (especially those who were morbidly obese) may have been passed over for a life-saving liver transplant. A recent study showed they may be just as viable candidates for the procedure as others in the patient population.